In April 2015, 4D Molecular Therapeutics signed a collaboration and license agreement to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Evolution TM, to identify and optimize novel vectors. This partnership was facilitated by QB3, a multi-campus University of California research institute and biotech accelerator, which seeks to catalyze relationships between large companies and startups at QB3’s incubators.
Roche is the world’s largest biotech company, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.